Clinical Trial Update: RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating radiotherapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus in first-line treatment of glioblastoma multiforme.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Bevacizumab (bevacizumab)
• Everolimus (everolimus)
• Temozolomide (Temozolomide)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2012-09-21